medigraphic.com

2005, Number 6

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2005; 43 (6)

Effectiveness and Security of Venlafaxine XR in the Treatment of Major Depression

Illescas-Rico R, Páez-Agraz F, Arreola-Chávez F, Verduzco-Fragoso W, García-Rosas FA, Luna-Soria F

Language: Spanish
References: 15
Page: 473-478
PDF size: 150.17 Kb.


ABSTRACT

Objectives: an open 4-month evaluation of the effectiveness, tolerability and safety of venla-faxine XR in the treatment of outpatients with major depression.
Material and methods: we conducted a multi-center, open, not placebo-controlled, phase IV clinical trial. Participants had to be outpatients, female or male, between 18 and 66 years of age, with a diagnosis of major depressive disorder according to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders-IV) and a minimal score of 20 points on the 21-item Hamilton Scale for Depression (HAM-D21). No patients with a deteriorated condition participated in this study. The evaluations confirmed the physical conditions of all participants as well as the application of HAM-D21 and Clinical Global Impressions (CGI) for up to 4 months. The doses managed for venlafaxine XR started with 75 mg/day, which was increased in the same proportion up to a maximum dose of 225 mg/day, depending on medical judgment. Descriptive statistics were used, t paired for HAM-D21 and CGI.
Results: 96 patients were recruited and partici-pated in this study, 74 patients completed the study. Baseline score for HAM-D21 was 30.9 ± 5.5 and the score for the final visit was 4.9 ± 6.1 (95 % CI, p ‹.0001). Baseline CGI score of 4.6 ± 1.2 and final CGI score of 1.5 ± 0.9 (95 % CI p ‹.0001), between baseline and final visit. The most frequent adverse events in a descending order were dry mouth, nausea, headache, somnolence, and dizziness. Five adverse events were catalogued and reported as serious adverse events. Patients did not show any modifications in laboratory analysis results, vital signs or weight.
Conclusion: this open evaluation of venlafaxine XR in a Mexican population shows the effecti-veness, good tolerability and safety of venla-faxine XR in the treatment of depression.


REFERENCES

  1. Üstünt TB, Ayuso-Mateos JL, Chaterji S, Mathers C, Murray CJL. Global bunden of depressive disorder in the year 2000. Br J Psychiatry 2004; 184:386-392.

  2. 2. Medina-Mora ME, et al. Prevalencia de trastornos mentales y uso de servicios: resultados de la En-cuesta Nacional de Epidemiología Psiquiátrica en México. Salud Mental 2003;26:1-16.

  3. 3. Ereshefsky L, Dugan D. Review of the pharmaco-kinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety 2000;12(Suppl 1):30-44.

  4. 4. Cunningham L. Once-dailyvenlafaxine extended frelase (xr) and venlafaxine immediate relas (ir) in out-patients with major depression. Ann Clin Psychiatry 1997;9:157-164.

  5. 5. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg SB. Antidepressant biochermical profile of te novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-4497.

  6. 6. Entsuah R, Derivan A, Kicta D. Early onset of antidepressant action of venlafaxine: pattern análisis in intent-to-treat patients. 1998;20:517-526.

  7. 7. Gutiérrez MG, Stimmel GL, Aiso JY. Venlafaxine: a 2003 update. Clin Ther 2003;25:2138-2154.

  8. 8. Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatry 1997;58: 393-398.

  9. 9. Simon JS, Aguiar LM, Kunz NR, Lei D. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder 2004;38:249-257.

  10. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV). Fourth edition. Washington, DC: American Psychiatric Association; 1994.

  11. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.

  12. Guy W. ECDEU assessment manual for psycho-pharmacology. Rockville, MD: US Department of Health and Human Services Publication (ADM); 1976. p. 218-222.

  13. Sthal SSM. Why settle for silver, when you can go for gold? Response vs. recovery as the goal of antide-pressant therapy. J Clin Psychiatry 1999;60:213-214.

  14. 14 Tylee A, Bowden M, Reynolds A. A double-blind, randomised, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderade to severe depression in general practice. Primary Care Psychiatry 1997;3:51-58.

  15. 15 Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants and placebo: analysis of FDA reports. Am J Psychiatry 2003;160:790-792.




2020     |     www.medigraphic.com